Suppr超能文献

艾哈迈德青光眼引流阀治疗难治性青光眼的长期疗效

Long-term success of ahmed glaucoma valve in refractory glaucoma.

作者信息

Kaya Mahmut, Ozbek Zeynep, Yaman Aylın, Durak Ismet

机构信息

Department of Ophthalmology, Dokuz Eylul University, Izmir, Turkey.

出版信息

Int J Ophthalmol. 2012;5(1):108-12. doi: 10.3980/j.issn.2222-3959.2012.01.22. Epub 2012 Feb 18.

Abstract

AIM

To evaluate the long-term results and complications of ahmed glaucoma valve (AGV) implantation in refractory glaucoma.

METHODS

A retrospective review of 13 patients (13 eyes) with refractory glaucoma who underwent AGV implantation and had a minimum follow-up of 18 months was performed. All patients underwent a complete ophthalmologic examination and intraocular pressure (IOP) measurement before surgery and at 1 month, 3 months, 6 months, 1 year after surgery and yearly afterwards. Complications and the number of antiglaucoma medications needed were recorded.

RESULTS

Mean age was 27.3±16.0 years. All eyes (100%) had at least one prior incisional surgery. Mean follow-up was 61.3±30.8 months. IOP was reduced from a mean of 35.0 ±7.0mmHg to 18.2±7.9mmHg at 12 months and to 17.0±4.1mmHg at 96 months (P<0.05) with a lower number of medications from baseline, 76.9% patients required additional procedures to achieve the success criteria set by previously published series. The most common complications were encapculated cyst formation in eight eyes (61.5 %) and tube exposure in four eyes (30.8%).

CONCLUSION

Encapsulated cyst formation was the most common complication which hindered succesful IOP control after AGV implant insertion for refractory glaucoma. Despite cyst excision with anti-fibrotic agents, successful IOP reduction was not achieved in 76.9% of the patients without antiglaucoma medication.

摘要

目的

评估艾哈迈德青光眼引流阀(AGV)植入术治疗难治性青光眼的长期疗效及并发症。

方法

回顾性分析13例(13眼)难治性青光眼患者,这些患者接受了AGV植入术,且至少随访18个月。所有患者在手术前、术后1个月、3个月、6个月、1年及之后每年均接受全面的眼科检查及眼压(IOP)测量。记录并发症及所需抗青光眼药物的数量。

结果

平均年龄为27.3±16.0岁。所有患眼(100%)均至少接受过一次既往切开手术。平均随访时间为61.3±30.8个月。眼压在12个月时从平均35.0±7.0mmHg降至18.2±7.9mmHg,在96个月时降至17.0±4.1mmHg(P<0.05),且药物使用数量较基线减少,76.9%的患者需要额外的手术以达到既往发表系列所设定的成功标准。最常见的并发症是8眼(61.5%)出现包裹性囊肿形成,4眼(30.8%)出现引流管暴露。

结论

包裹性囊肿形成是最常见的并发症,阻碍了AGV植入术治疗难治性青光眼后眼压的成功控制。尽管采用抗纤维化药物切除囊肿,但76.9%未使用抗青光眼药物的患者眼压未能成功降低。

相似文献

1
Long-term success of ahmed glaucoma valve in refractory glaucoma.艾哈迈德青光眼引流阀治疗难治性青光眼的长期疗效
Int J Ophthalmol. 2012;5(1):108-12. doi: 10.3980/j.issn.2222-3959.2012.01.22. Epub 2012 Feb 18.

引用本文的文献

4
Safety and Efficacy of Ahmed Valve on Intractable Glaucoma in Saudi Population.艾哈迈德引流阀在沙特人群中治疗难治性青光眼的安全性和有效性
Middle East Afr J Ophthalmol. 2020 Apr 29;27(1):40-46. doi: 10.4103/meajo.MEAJO_249_19. eCollection 2020 Jan-Mar.
8
The Results of the Use of Ahmed Valve in Refractory Glaucoma Surgery.艾哈迈德阀门在难治性青光眼手术中的应用结果
J Curr Glaucoma Pract. 2015 Sep-Dec;9(3):86-91. doi: 10.5005/jp-journals-10008-1191. Epub 2016 Feb 2.
9
Tube Exposure Repair.导管暴露修复
J Curr Glaucoma Pract. 2012 Sep-Dec;6(3):139-42. doi: 10.5005/jp-journals-10008-1121. Epub 2012 Oct 16.

本文引用的文献

1
Second Ahmed valve insertion in the same eye.同一只眼睛再次植入艾哈迈德人工房水引流阀。
J Glaucoma. 2009 Apr-May;18(4):336-40. doi: 10.1097/IJG.0b013e318182edfb.
5
Glaucoma drainage implants: a critical comparison of types.青光眼引流植入物:类型的关键比较
Curr Opin Ophthalmol. 2006 Apr;17(2):181-9. doi: 10.1097/01.icu.0000193080.55240.7e.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验